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Increased mitochondrial biogenesis by activation of
PPAR- or AMPK/PGC-1a-dependent homeostatic
pathways has been proposed as a treatment for
mitochondrial disease. We tested this hypothesis
on three recombinant mouse models characterized
by defective cytochrome c-oxidase (COX) activity: a
knockout (KO) mouse for Surf1, a knockout/knockin
mouse for Sco2, and a muscle-restricted KO mouse
for Cox15. First, we demonstrated that double-
recombinant animals overexpressing PGC-1a in
skeletal muscle on a Surf1 KO background showed
robust induction of mitochondrial biogenesis and
increase of mitochondrial respiratory chain activities,
including COX. No such effect was obtained by treat-
ing both Surf1/ and Cox15/ mice with the pan-
PPAR agonist bezafibrate, which instead showed
adverse effects in either model. Contrariwise, treat-
ment with the AMPK agonist AICAR led to partial
correction of COX deficiency in all three models,
and, importantly, significant motor improvement up
to normal in the Sco2KO/KI mouse. These results
open new perspectives for therapy of mitochondrial
disease.
INTRODUCTION
Present in virtually all eukaryotes, mitochondria are the major
source of the high-energy phosphate molecule adenosine tri-
phosphate (ATP), which is synthesized by the mitochondrial
respiratory chain (MRC) through the process of oxidative phos-
phorylation (OXPHOS) (Wallace, 2005). ATP is the principal
energy substrate required for all active processes within the
cell, and ATP deficiency leads to cellular dysfunction and ulti-
mately cell death. A host of pathways and enzymatic functions
residing within mitochondria canmodify and influence OXPHOS,
and OXPHOS abnormalities can in turn generate signals that
trigger either homeostatic pathways, e.g., mitochondrial biogen-
esis, or execution programs, e.g., mitophagy, which eliminates80 Cell Metabolism 14, 80–90, July 6, 2011 ª2011 Elsevier Inc.single dysfunctional organelles, or apoptosis, which eliminates
the whole dysfunctional cell (Goldman et al., 2010).
A complex, finely tuned homeostatic system senses the
dynamic balance between energy demand and expenditure
and regulates the biogenesis, activity, and coupling of mitochon-
dria, according to type, function, and metabolic status of cells
and tissues (Wallace and Fan, 2010). In mammals, a master
regulator of mitochondrial biogenesis is PPAR-gamma Coacti-
vator 1 alpha (PGC-1a), a transcriptional coactivator that is phys-
iologically induced or activated by conditions of shortage of, or
increased demand for, energy, such as cold, physical activity
and fasting (Handschin and Spiegelman, 2006). PGC-1a acts
by interacting with, and increasing the activity of, a number of
transcription factors that in turn induce genes directly or indi-
rectly related to mitochondrial proliferation, oxidative catabo-
lism, and respiration. For instance, PGC-1a interacts with, and
potentiates the function of, nuclear respiratory factors (NRF1
and NRF2) and a, b/d, and g isoforms of the peroxisomal
proliferator activated receptors (PPARs). Both NRF1 and NRF2
induce the expression of several nucleus-encoded subunits of
MRC complexes, and of genes involved in replication and tran-
scription of mtDNA, including Tfam (Kelly and Scarpulla, 2004).
PPARs are tissue-specific, or ubiquitously expressed, nuclear
receptors of fatty acids, which act as their activating ligands.
The principal action of PPARs is to induce transcription of
genes encoding enzymes involved in cellular and organelle
uptake of fatty acids and fatty acid oxidation (FAO), in both mito-
chondria and peroxisomes (Lefebvre et al., 2006; Barish et al.,
2006). PGC-1a is activated by posttranslational modifications,
including phosphorylation and deacetylation. Phosphorylation
at PGC-1a T177 and S538 residues is operated by the AMP-
dependent kinase (AMPK) (Ja¨ger et al., 2007). Again, this activa-
tion responds to a physiological homeostatic mechanism, since
ATP and AMP are part of the same nucleotide pool, their levels
being inversely related, so that when shortage of the former
occurs, the latter increases, and vice versa. As a consequence
of increased AMP levels, reflecting low ATP availability and
low energy reserve, AMPK is activated, resulting in a cascade
of phosphorylation-dependent adaptive modifications of several
factors, including PGC-1a, that ultimately determine the shut-
down of anabolic, energy-consuming processes, whereas cata-
bolic, energy-producing pathways, such as FAO and MRC,
are switched on. AMPK activates PGC-1a not only by direct
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activating the NAD+-dependent deacetylase sirtuin 1, Sirt1,
which in turn increases the amount of deacetylated, active
form of PGC-1a (Canto´ et al., 2009). Sirt1 activation by AMPK
is mainly due to increased NAD+/NADH ratio, a condition that
stimulates Sirt1, as a consequence of AMPK-mediated in-
creased expression of FAO (and OXPHOS) genes, and also of
the Nampt gene, encoding the enzyme that converts nicotin-
amide into NAD+ (Canto´ et al., 2009). AMPK is a heterotrimer
consisting of a catalytic a subunit and two regulatory subunits,
b and g. The latter subunits exist as multiple isoforms, giving
12 different possible combinations of holoenzyme with different
tissue distribution and subcellular localization. AMPK is alloste-
rically stimulated by AMP and is itself regulated by phosphoryla-
tion via two main upstream AMPK kinases (Canto´ and Auwerx,
2010; Steinberg and Kemp, 2009). The major regulatory phos-
phorylation site of AMPK has been identified as T172 within the
catalytic loop between the DFG and APE motifs of the a subunit
(Fogarty et al., 2010). Besides physiological conditions, PGC-1a
and PPARs can also be stimulated or induced pharmacologi-
cally. For instance, bezafibrate is a pan-PPAR agonist that is
widely used to treat the metabolic syndrome and hyperlipid-
emias (Tenenbaum et al., 2005). Resveratrol, a natural poly-
phenol compound, activates PGC-1a via Sirt1 (Lagouge et al.,
2006), and 5-aminoimidazole-4-carboxamide ribonucleoside
(AICAR) does so by generating inosine monophosphate, which
acts as an AMPK agonist by mimicking AMP (Corton et al.,
1995; Merrill et al., 1997).
Mitochondrial disorders are clinical entities associated with
defects of OXPHOS, which are ultimately genetically deter-
mined (Wallace, 2010). Mitochondrial disorders can be deter-
mined by mutations in mtDNA, or in OXPHOS-related nuclear
genes (Zeviani and Di Donato, 2004). Many pathogenic mtDNA
mutations are heteroplasmic, i.e., they coexist with a variable
percentage of wild-type mtDNA. Clinical symptoms typically
ensue when the amount of mutant mtDNA offsets a critical
threshold, usually >50%–60% of total mtDNA, below which
the mutation has virtually no clinical impact. Likewise, most of
the mitochondrial syndromes due to mutations in nuclear genes
behave as recessive traits and in many cases are determined
either by mutations in ‘‘ancillary’’ proteins that play an arguably
relevant, but nevertheless not essential, often partially redun-
dant, role in OXPHOS, or by hypomorphic mutant alleles encod-
ing a crippled but still partially functional protein. These obser-
vations have suggested the hypothesis that the deleterious
effects of either mtDNA- or nuclear-gene mutations could be
overcome, at least partially, by increasing the total amount of
mitochondria and/or of functionally active ‘‘MRC units,’’ via acti-
vation of the mitochondrial biogenesis program in critical
tissues (Bastin et al., 2008; Wenz et al., 2008). This idea has first
been tested in cells from mitochondrial disease patients, by
overexpressing recombinant PGC-1a or by adding bezafibrate
in the medium (Bastin et al., 2008; Srivastava et al., 2009).
Both treatments showed mutant cells to partially recover MRC
activities and increase ATP production. Oral bezafibrate has
later been reported to ameliorate the clinical conditions and
the biochemical impairment of a cre-lox murine model of COX-
defective myopathy, determined by muscle-specific ablation
of Cox10, the heme b farnesyl transferase, by expressing thecre recombinase under the myosin light-chain 1F (MLC1F)
promoter. Here, we report the results of experimental treat-
ments carried out on three other mouse models of COX defi-
ciency: (1) a Surf1 constitutive knockout (KO) mouse, (2) a
muscle-specific Cox15 KO mouse, and (3) a constitutive
knockout/knockin Sco2 mouse (Sco2KO/KI) (Yang et al., 2010)
carrying a null Sco2 allele and a second Sco2 allele with
a missense mutation E129K, corresponding to the E140K recur-
rent, pathogenic change in SCO2 mutant patients. Absence of
Surf1, an assembly factor of COX, causes severe COX defi-
ciency and fatal Leigh syndrome in children, but milder COX
deficiency, and hardly any clinical sign, in mice (Dell’Agnello
et al., 2007). Mutations in Cox15, the key enzyme for the
conversion of heme o into heme a (Khalimonchuk and Ro¨del,
2005), lead to fatal encephalocardiomyopathy in children (Anto-
nicka et al., 2003; Bugiani et al., 2005) and severe myopathy
with marked COX deficiency in muscle-restricted KO mice
(this paper). Sco2 is a metallochaperone involved in copper
metallation of COX (Leary et al., 2009), mutations in which
lead to infantile fatal encephalocardiomyopathy (Papadopoulou
et al., 1999).
RESULTS
Overexpression of PGC-1a Increases MRC Activities
We first investigated a transgenic mouse that overexpresses
PGC-1a under the promoter of the skeletal-muscle-specific
creatine-kinase (MCK) gene (MCK-PGC-1a). Muscle-restricted
overexpression of the PGC-1a gene in the transgenic individuals
was 10.7 ± 2.9-fold that of controls, resulting in a 4-fold steady-
state increase in the amount of the PGC-1a protein (Figure 1A).
The MCK-PGC-1a mice are vital, with hardly any clinically rele-
vant features; however, they did show a 3- to 4-fold increase in
both muscle mtDNA content (from 1900 ± 674 to 6706 ± 394
copies/cell) and citrate synthase (CS) activity in muscle homog-
enate (from 337.9 ± 48.6 to 948.4 ± 139.3 nmol/min/mg of
protein), two indexes of mitochondrial mass, compared to WT
littermates (Figures 1B and 1C). We also determined the expres-
sion levels of the immediate targets of PGC-1a, i.e., Nrf1 and
Nrf2, and of several downstream targets of the latter factors,
including Tfam, COI, COII, COXIV, and COX5a (Figure 1D). The
mRNA levels of both Nrf genes remained unchanged, whereas
the downstream genes were all overexpressed 2- to 3-fold in
MCK-PGC-1a muscle samples, compared to those of WT
littermates. These findings are fully compatible with the role of
PGC-1a as a coactivator that increases the transcriptional
activity of several factors, including the Nrf’s, but is not a tran-
scription factor by itself. Increased expression of COX subunit
transcripts was correlated to increased amount of the corre-
sponding proteins, demonstrated by quantitative western blot
(WB) immunovisualization (Figure 1A), which resulted in a 1.5-
to 2-fold increase in the specific activities of MRC complexes,
cI cII, cIII, and cIV (Figure 1C).
PGC-1a is also known to activate factors, e.g., PPARs, that
increase the cellular and organelle uptake, and the catabolic
oxidation, of fatty acids (FAO). This effect was reflected by
a 3.5-fold increased expression inMCK-PGC-1amouse muscle
of CD36/FAT, a gene encoding the plasma membrane trans-
porter of fatty acids (Figure 1D).Cell Metabolism 14, 80–90, July 6, 2011 ª2011 Elsevier Inc. 81
Figure 1. Effects of PGC-1a Overexpres-
sion in Surf1–/– Mice
(A) Expression analysis of PGC-1a. (Left panel)
The PGC-1a transcript from muscle of each
mouse genotype (three animals/genotype) was
retrotranscribed into cDNA, normalized to that of
the Hprt gene, and expressed as time-fold varia-
tions relative to the values obtained fromwild-type
(WT) animals. Solid blue, WT; blue outline, PGC-
1a: MCK-PGC-1a transgenic mouse; solid red,
Surf1/, constitutive Surf1 knockout mouse; red
outline,Surf1//PGC-1a:Surf1//MCK-PGC-1a
double mutant mouse. Error bars represent the
standard deviation (SD). (Right panel) Western blot
immunovisualization of skeletal muscle proteins of
the different genotypes, listed as above. Densito-
metric analysis of each band, normalized against
that of GAPDH, revealed the following variations,
relative to WT. (1) PGC-1a, 4.3 in MCK-PGC-1a;
0.5 in Surf1/; 2.2 in Surf1//PGC-1a. (2) COX1,
1.8 in MCK-PGC-1a; 0.2 in Surf1/; 1.0 in
Surf1//PGC-1a. (3) COX5a, 5.0 in MCK-PGC-
1a; 0.0 in Surf1/; 1.0 in Surf1//PGC-1a.
(B) MtDNA analysis in different genotypes (three
animals/genotype). Color code is as in (A). MtDNA
is expressed as number of DNAmolecules per cell
(Cree et al., 2008). Error bars represent SD.
(C) MRC activities in the different genotypes (three animals/genotype), expressed as nmoles/min/mg of protein. Note that the activity of cII has been multiplied by
10 for visualization clarity. Color code is as in (A). CS, citrate synthase; CI-IV, MRC complexes I–IV. Error bars represent the standard deviation (SD). The asterisks
represent the significance levels calculated by unpaired, Student’s two-tailed t test: *p < 0.05; **p < 0.01; ***p < 0.001.
(D) Expression analysis of FAO- and OXPHOS-related genes in WT, Surf1/, MCK-PGC-1a, MCK-PGC-1a/Surf1/ muscles of mice. The levels of the gene
transcripts, retrotranscribed into cDNA, were normalized to that of the Hprt gene transcript and expressed as time-fold variation relative to the WT. Error bars
represent SD. The asterisks represent the significance levels calculated by unpaired, Student’s two-tailed t test: *p < 0.05; **p < 0.01; ***p < 0.001.
(E) COX staining in muscles from different mouse lines including wild-type (WT), Surf1/, MCK-PGC1a, and MCK-PGC1a/Surf1/ individuals. Note that the
reaction is increased in the PGC1a overexpressing mouse models compared to the corresponding naive models. Scale bar, 25 mm, magnification 203.
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specificMRCdefects in vivo,we thencarriedout suitable crosses
that transferred the MCK-PGC-1a allele into a COX-defective
model due to the constitutive ablation ofSurf1. Surf1 is a putative
assembly factor specific to COX, its absence being associated
with profound COX deficiency in humans (%10%–15% of the
lower normal limit in different cell types) and, albeit milder, in
mice as well (typically 30%–40% of the lower normal limit). While
the loss of Surf1 causes early onset, invariably fatal Leigh
encephalopathy in patients, recombinant null mice showed
hardly any clinically deleterious consequence, and standard
treadmill test showed no locomotor impairment.
The skeletal muscle of Surf1//MCK-PGC-1a double mutant
mice did show the same effects detected inMCK-PGC-1a trans-
genic muscles: increased mtDNA content (from 2078 ± 693 to
4079 ± 824 copies/cell) and CS activity (from 343 ± 33 to 934 ±
226 nmol/min/mg) (Figures 1B and 1C), increased levels of
CD36/FAT transcript, and increased levels of COX-specific
mRNA and protein subunits (Figures 1A and 1D). These changes
resulted in (1) partial but significant recovery of COX specific
activity (1.6-fold, from 104 ± 24 to 162 ± 42 nmol/min/mg; p =
0.02) (Figure 1C), which nevertheless remained well below the
normal range (370 ± 49 nmol/min/mg); and (2) increased histo-
chemical reaction to COX (Figure 1E). Taken together, these
data suggest that overexpression of PGC-1a induces mitochon-
drial biogenesis and can partially correct a specific defect of
COX in vivo.82 Cell Metabolism 14, 80–90, July 6, 2011 ª2011 Elsevier Inc.Bezafibrate Induces Expression of FAO- but Not
OXPHOS-Related Genes
In a second set of experiments, we then tested the effects of
PPAR activation in the Surf1/ mouse model. To this end,
the same genes, proteins, and activities measured in the
MCK-PGC-1a and Surf1//MCK-PGC-1a mouse models
were also measured in Surf1/ and WT littermates exposed
to 0.5% bezafibrate, mixed in standard food for 1 month
(Wenz et al., 2008). We observed significant body weight loss
during the treatment and marked hepatomegaly at the end of
treatment, in both Surf1/ andWT animals (see Figure S1 avail-
able online), indicating toxicity of this drug in mice. As expected,
the expression of PPAR b/d and PPAR a, the two PPAR
isoforms present in skeletal muscle, was significantly increased
in treated animals, along with FAO-related genes, including
CD36/FAT, ACOX, encoding acylCoA oxidase, and SCAD,
encoding short-chain acylCoA dehydrogenase (Figure 2A).
Taken together, these data clearly demonstrated that bezafi-
brate treatment was indeed effective on the main targets
specific for this drug in vivo. Contrariwise, no significant change
in mtDNA content, CS, and MRC activities was measured in
treated versus untreated Surf1/ or WT muscles (Figures 2B
and 2C), and the histochemical reaction to COX was equally
defective in both treated and untreated Surf1/ specimens
(Figure 2D). Accordingly, the expression of PGC-1a, both
NRFs, and Tfam remained unchanged among the different
groups of animals, as did several COX subunit transcripts,
Figure 2. Bezafibrate Treatment on the
Surf1–/– Mouse Model
(A) Expression analysis of FAO- and OXPHOS-
related genes in Surf1/ and WT muscles of
bezafibrate (bzf)-treated and untreatedmice. Solid
blue, WT, untreated; blue outline, bzf-treated WT;
solid red, Surf1/, untreated; red outline, bzf-
treatedSurf1/. The levels of the gene transcripts,
retrotranscribed into cDNA, were normalized to
that of the Hprt gene transcript and expressed as
time-fold variation relative to the WT. Error bars
represent SD. The asterisks represent the signifi-
cance levels calculated by unpaired, Student’s
two-tailed t test: *p < 0.05; **p < 0.01.
(B) MtDNA content analysis in the different geno-
types. The color codes are as in (A). Error bars
represent SD. MtDNA is expressed as number of
DNA molecules per cell (Cree et al., 2008).
(C) MRC activities in the different genotypes, ex-
pressed as nmoles/min/mg of protein. Note that
the activity of cII has been multiplied by 10 for
visualization clarity. Color code is as in (A).
(D) COX staining in muscles from Surf1/ andWT
muscles of bzf-treated and untreated mice. Scale
bar, 25 mm, magnification 203.
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genes (Figure 2A).
A Muscle-Specific Cox15 KO Mouse Displays
COX-Defective Mitochondrial Myopathy
Since our results failed to confirm those on bezafibrate treatment
reported in the MLC1F-Cox10/ mouse model (Wenz et al.,
2008), we created a KO mouse for the Cox15 gene, using the
cre-lox technology (Figures S2A and S2B). The Cox15 gene
product is the enzyme that comes next to Cox10 in the biosyn-
thetic pathway of heme a, the COX-specific heme moiety.
Cox10 adds a farnesyl chain to heme b, converting it into
heme o, which can then be inserted into the protein backbone
of nascent COX. Cox15 eventually converts heme o into func-
tionally active heme a by oxidation of the C8-methyl group (Kha-
limonchuk and Ro¨del, 2005). The constitutive Cox15/ animals,
obtained by crossing Cox15loxP/loxP mice with a general cre-de-
leter transgenic mouse, showed consistent embryonic lethality
at %7.5 dpc (not shown). We then produced a muscle-specific
Cox15/ model by crossing Cox15loxP/loxP with a transgenic
mouse expressing the cre recombinase under the control of
the human skeletal muscle-specific a-actin (ACTA1) promoter
(ACTA-Cox15/ mouse).
Recombination of the Cox15 locus by the cre recombinase
was detected only in skeletal muscle and, in trace amount, in
the heart, whereas no recombination occurs in other tissues
(Figure S2C). Accordingly, the amount of Cox15 mRNA in
ACTA-Cox15/ mouse skeletal muscle was %16% than that
of WT muscle (Figure 3A), and so was the COX/CS ratio
(0.05 ± 0.02 in ACTA-Cox15/ versus 0.66 ± 0.06 in WT),
whereas there was no significant difference in other tissues
(Figure 3B). Albeit born at the expected mendelian ratio, the
ACTA-Cox15/ mice were smaller than WT littermates at
30 days after birth (data not shown) and had significantly
reduced motor performance measured by a standard treadmill
test, initially administered to 4-week-old individuals, and thenrepeated at 6, 8, 12, and 16 weeks (Figure 3C). Histochemical
analysis in skeletal muscle confirmed severe reduction of COX
and compensatory proliferation of aberrant mitochondria (Fig-
ure 3D), which was confirmed by increased mtDNA content
(Figure 3E), increased cII and CS activities (Table S1), and
increased SDH histochemical reaction (data not shown), in
ACTA-Cox15/ muscles. COX histochemistry was normal in
other tissues (data not shown). Except for cII activity, which
increased from 24.2 ± 4.2 in WT to 34.9 ± 7.8 in ACTA-Cox15/
muscle homogenate, other MRC activities, including cI and cIII,
in muscle (Table S1), and all the MRC activities in nonmuscle
tissues (data not shown), of ACTA-Cox15/ were comparable
to those of WT littermates.
Bezafibrate Is Highly Toxic to ACTA-Cox15–/– Mice
We then tested the response of eight ACTA-Cox15/ female
mice to bezafibrate, according to the same protocol used on
the Surf1/ and MLC1F-Cox10/ models. However, after
24–48 hr from the treatment start, the ACTA-Cox15/ animals
became critically ill, prompting us to euthanize them. We found
worsening of the mitochondrial myopathy (Figures S3A and
S3B), and massive apoptosis, demonstrated by numerous
TUNEL-positive nuclei (Figures S3C and S3D), corresponding
ultrastructurally to chromatin condensation and apoptotic
bodies (Figures S3E and S3F). No increased levels of plasma
creatine kinase, urea, creatinine, or lactate were detected in
plasma of euthanized animals, as observed in massive rhabdo-
myolysis and acute kidney failure, an adverse effect occasionally
reported in patients under bezafibrate treatment (Charach et al.,
2005; Wu et al., 2009).
AICAR Induces FAO and OXPHOS Genes in Surf1–/–,
Sco2KO/KI, and ACTA-Cox15–/– Muscle
In a third set of experiments, we tested the capacity of AICAR, an
AMPK agonist, to activate PGC-1a in our animal models. AICAR
was given for 1 month in daily subcutaneous injections ofCell Metabolism 14, 80–90, July 6, 2011 ª2011 Elsevier Inc. 83
Figure 3. Characterization of the ACTA-Cox15–/– Mouse Model
(A) Cox15 transcript levels in skeletal muscle. The Cox15-specific mRNA content is 15% in ACTA-Cox15/ relative to the parental Cox15lox/lox mouse line,
considered as wild-type (WT). The levels of the Cox15 gene transcripts, retrotranscribed into cDNA, were normalized to that of the Hprt gene transcript and
expressed as time-fold variation relative to theWT. Three animals were used for each genotype. Error bars represent SD. The asterisks represent the significance
levels calculated by unpaired, Student’s two-tailed t test: ***p < 0.001.
(B) COX (CIV)-specific activity normalized to that of citrate synthase (CS) in tissues from ACTA-Cox15/mice. M, muscle; B, brain; H, heart; L, liver. Error bars
represent SD. The asterisks represent the significance levels calculated by unpaired, Student’s two-tailed t test, ***p < 0.001.
(C) Treadmill analysis of ACTA-Cox15/ mice at different time points. The dotted line indicates the lower limit of the motor performance of the parental
Cox15lox/lox mouse line, considered as WT. Note the rapidly progressive reduction of motor endurance in the ACTA-Cox15/mouse line over time. Six animals
were used for each genotype. Error bars represent SD.
(D) (Top) COX staining from ACTA-Cox15/ skeletal muscle. The inset shows the reaction in a Cox15lox/lox (WT) muscle, for comparison. Magnification, 203.
(Bottom) Electron microscopy analysis of ACTA-Cox15/ skeletal muscle. Note the subsarcolemmal accumulation of mitochondria in (Db) (magnification,
70003) and the presence of an abnormal mitochondria characterized by disruption of the inner membrane and accumulation of electron dense material in (Dc)
and (Dd) (magnification, 16,0003 and 20,0003, respectively).
(E) MtDNA content in Cox15lox/lox (WT) and ACTA-Cox15/ skeletal muscles. Error bars represent SD. The asterisk represents the significance levels calculated
by unpaired, Student’s two-tailed t test, *p < 0.05.
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COX Defect Correction by AMPK/PGC-1a Activation0.25 mg/day/gm of body weight to 2-month-old Surf1/,
Sco2KO/KI, and WT littermates, and of 0.5 mg/day/gm to
2-month-old ACTA-Cox15/ animals and WT littermates,
each group being composed of three/four individuals (see
legends of Figures 4–6 for details). At the end of treatment, the
mtDNA content (data not shown) and CS activity in skeletal
muscle (Table S2) were similar in each treated group versus
the corresponding untreated group. Analysis of selected tran-
scripts (Figures 4A, 5A, and 6A) showed that, similar to the
MCK-PGC-1a overexpressing mice, Nrf1 and Nrf2 gene expres-
sion was unchanged in all groups; however, both Tfam and the
COX subunit encoding genes were significantly increased in
treated versus untreated Surf1/ (p < 0.05), Sco2KO/KI (p <
0.01), and ACTA-Cox15/ muscles (p < 0.01). Increased
expression of these genes was observed in treated WT mice
exposed to the higher (0.5 mg/gm) but not to the lower
(0.25 mg/gm) dosage (p < 0.01). The expression of the FAO-
related CD36/FAT gene was significantly increased in all treated
groups. PDK4 andUCP3, two genes that are activated by AMPK84 Cell Metabolism 14, 80–90, July 6, 2011 ª2011 Elsevier Inc.independently from PGC-1a, were also increased under AICAR
treatment. Immunovisualization of selected proteins (Figures
4B, 5B, and 6B) showed that increased expression of COX
subunit genes was paralleled by increased amount of COX1
and COX5a proteins in treated Surf1/, Sco2KO/KI, and ACTA-
Cox15/mice, resulting in significantly increased COX-specific
activity (Figures 4C, 5C, and 6C and Tables S2–S4; p < 0.01). We
also immunovisualized T172-phosphorylated (AMPK-P
T172)
versus total muscle AMPK (Figures 4B, 5B, and 6B). Interest-
ingly, the levels of AMPK-PT172 were already 8-fold higher in
untreated Surf1/ than in untreated WT mice, whereas total
AMPK was unchanged. A similar result was obtained in the
untreated ACTA-Cox15/ and, albeit less pronounced, in
Sco2KO/KI muscles. AICAR further increased AMPK phosphory-
lation in all three COX-defective models, and in WT littermates
as well. The quantitative biochemical results obtained by spec-
trophotometric assays (Figures 4C, 5C, and 6C and Tables S2,
S3, and S4) were paralleled by a similar, albeit merely qualitative,
trend shown by histochemical reactions to COX (Figures 4D,
Figure 4. AICAR Treatment in Surf1–/– Mice
(A) Expression analysis of FAO- and OXPHOS-
related genes in Surf1/ and WT muscles of
AICAR-treated (0.25 mg/day/gm) and untreated
mice. Solid blue, WT, untreated; blue outline,
AICAR-treated WT; solid red, Surf1/, untreated;
red outline, AICAR-treated Surf1/. The levels of
the gene transcripts, retrotranscribed into cDNA,
were normalized to that of theHprt gene transcript
and expressed as time-fold variation relative to
the WT. Error bars represent SD. The asterisks
represent the significance levels calculated by
unpaired, Student’s two-tailed t test: *p < 0.05;
**p < 0.01; ***p < 0.001.
(B) Western blot immunovisualization of skeletal
muscle proteins of the different genotypes, listed
as above. Densitometric analysis of each band,
normalized against that of GAPDH, revealed the
following variations, relative to untreated WT. (1)
PGC-1a: 1.1 in WT+AICAR; 1.5 in Surf1/; 1.8
in Surf1/+AICAR. (2) Total AMPK: 0.8 in
WT+AICAR; 1.0 in Surf1/; 0.9 in Surf1/+
AICAR. (3) AMPK-PT172: 2.3 in WT+AICAR; 8.2 in
Surf1/; 9.5 in Surf1/+AICAR. COX1: 1.0 in
WT+AICAR; 0.2 in Surf1/; 0.6 in Surf1/+
AICAR. (4) COX5a: 1.1 in WT+AICAR; 0.04 in
Surf1/; 0.6 in Surf1/+AICAR.
(C) MRC activities in the different genotypes,
AICAR-treated or untreated, expressed asnmoles/
min/mg of protein. Note that the activity of cII has been multiplied by 10 for visualization clarity. Error bars represent SD.
(D) COX staining in skeletal muscles from AICAR-treated and untreated Surf1/ andWT littermates. Note the increased staining of the Surf1/+AICAR sample.
Magnification, 203.
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Cox15/mice, bymarked decrease of ultrastructural abnormal-
ities in mitochondria (Figure 6D). Taken together, these results
indicate a compensatory activation of the AMPK-Pgc1a axis in
conditions of defective COX activity.
Effect of AICAR Treatment on Motor Performance
In order to evaluate the clinical effect of treatment, we adminis-
tered a standard, quantitative incremental motor endurance
test using a treadmill device. The motor performance was similar
to WT littermates in untreated Surf1/ mice, significantly
impaired in Sco2KO/KI mice, and extremely impaired in ACTA-
Cox15/ mice, which were able to walk on the treadmill for
just a couple of minutes (Figure 7A). Since no motor phenotype
was detected in Surf1/ mice, we focused our analysis on the
other two COX-defective models that did show motor impair-
ment. In treated Sco2KO/KI mice, the biochemical improvement
was mirrored by marked amelioration of motor performance,
which reached the same score as the untrained WT littermates
by the first to second week of treatment (Figure 7B). Contrari-
wise, and in spite of partial biochemical recovery, we found no
change by treadmill test in ACTA-Cox15/ mice, suggesting
that the mitochondrial myopathy was too severe for AICAR
treatment to achieve a clinically detectable effect (Figure 7C).
DISCUSSION
There is no effective treatment for mitochondrial disorders, and
current clinical management is focused on treating complica-
tions. Stimulation of mitochondriogenesis and MRC activity isone of the strategies that have been proposed to correct
OXPHOS failure leading to these conditions.
Two principal systems, PGC-1a and PPARs, are known to
increase mitochondrial aerobic metabolism, acting on different,
albeit partially overlapping, sets of genes related to mitochon-
drial bioenergetic pathways.
PGC-1a functions as a coactivator, i.e., it interacts with a
number of transcription factors, potentiating their induction of
mitochondrial bioenergetics-related genes, including those of
OXPHOS. The mechanisms that regulate the expression and
activity of PGC-1a are only partially known, but an important
role is certainly played by posttranslational modifications of
this protein, such as deacetylation, mediated by Sirt1, and phos-
phorylation, mediated by AMPK.
The control on energy metabolism by PPARs is centered on
the activation of mitochondrial FAO, which in turn feeds both
the tricarboxylic acids cycle and the MRC. While PPARs are
clearly induced by activation of PGC-1a, the opposite effect,
i.e., PPAR-dependent induction of PGC-1a, is questioned.
In principle, the activation of Sirt1 by NAD+, produced by
FAO, links the PPARs system to mitochondriogenesis and OX-
PHOS, activated by PGC-1a. Another possible mechanism is
the direct PPAR-dependent induction of PGC-1a mediated by
a PPAR-responsive element present in the promoter region
of the PGC-1a gene. While the latter mechanism has been
shown to be active in vitro, several reports have failed to demon-
strate a physiologically effective PPAR-dependent control on
PGC-1a expression and activity in mammalian organisms
(Luquet et al., 2003; Wang et al., 2004; Kleiner et al., 2009).
However, these mechanisms have been proposed to explainCell Metabolism 14, 80–90, July 6, 2011 ª2011 Elsevier Inc. 85
Figure 5. AICAR Treatment in Sco2KO/KI Mice
(A) Expression analysis of FAO- and OXPHOS-related genes in Sco2KO/KI and WT muscles of AICAR-treated (0.25 mg/day/gm) and untreated mice. Solid blue,
WT, untreated; blue outline, AICAR-treated WT; solid red, Sco2KO/KI, untreated; red outline, AICAR-treated Sco2KO/KI. The levels of the gene transcripts,
retrotranscribed into cDNA, were normalized to that of the Hprt gene transcript and expressed as time-fold variation relative to the WT. Error bars represent SD.
The asterisks represent the significance levels calculated by unpaired, Student’s two-tailed t test: *p < 0.05; **p < 0.01; ***p < 0.001.
(B) Western blot immunovisualization of skeletal muscle proteins of the different genotypes, listed as above. Densitometric analysis of each band, normalized
against that of GAPDH, revealed the following variations, relative to untreated WT. (1) PGC-1a: 1.7 in WT+AICAR; 1.0 in Sco2KO/KI; 1.7 in Sco2KO/KI+AICAR. (2)
Total AMPK: 1.0 inWT+AICAR; 1.2 in Sco2KO/KI; 1.2 in Sco2KO/KI+AICAR. (3) AMPK-PT172: 1.8 inWT+AICAR; 1.6 in Sco2KO/KI; 3.2 in Sco2KO/KI+AICAR. COX1: 1.1
in WT+AICAR; 0.6 in Sco2KO/KI; 0.8 in Sco2KO/KI+AICAR. (4) COX5a: 1.0 in WT+AICAR; 0.5 in Sco2KO/KI; 0.7 in Sco2KO/KI+AICAR.
(C) MRC-specific activities in the different genotypes, AICAR-treated or untreated, expressed as nmoles/min/mg of protein. Note that the activity of cII has been
multiplied by 10 for visualization clarity. Error bars represent SD.
(D) COX and SDH staining in skeletal muscles from AICAR-treated and untreated Sco2KO/KI and WT littermates. Note the increased staining of the
Sco2KO/KI+AICAR sample. Magnification, 203.
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able to correct theCOXdefect, amelioratemotor impairment, and
prolong life span, inMLC1F-Cox10/, amousemodel character-
izedbymuscle-selectiveablationofCox10,ahemeabiosynthetic
enzyme.
To confirm and extend these observations in vivo, we first
sought for a proof-of-principle demonstration by showing that
(1) marked overexpression of transgenic Pgc1a increases the
mtDNA content (Lin et al., 2002) and activities of the MRC
complexes (this paper) on a WT background; and (2) is also
able to partially, albeit not completely, correct COX deficiency
in the skeletal muscle of a mildly COX-defective mammalian
model, i.e., a constitutive Surf1/ recombinant mouse. These
data are largely concordant with results previously obtained in
the MLC1F-Cox10/ mouse, and indicate that vigorous stimu-
lation of the Pgc1a axis is effective in increasing OXPHOS in
normal and disease conditions in vivo.
Next, we tested the effects of the pharmacological activation
of either PPARs- or PGC-1a-regulatory systems in our mouse86 Cell Metabolism 14, 80–90, July 6, 2011 ª2011 Elsevier Inc.models. Although these models differ in the severity of biochem-
ical impairment and clinical outcome, all maintain some residual
COX activity in skeletal muscle, similar to the corresponding
human conditions. This biochemical ‘‘leakiness’’ occurs by dif-
ferent mechanisms in the different mutant organisms. For
instance, the function of Surf1 is known to be partially redundant
in humans (Tiranti et al., 1999), and even more so in mice
(Dell’Agnello et al., 2007). Likewise, while the complete
ablation of Sco2 leads to embryonic lethality (Yang et al., 2010),
the combination of a null allele with an allele carrying a missense
mutation prevents the activity of the Sco2 protein from being
completely abolished. In turn, the excision of Cox15 in the
ACTA-Cox15/ mouse affects a high percentage but not all
the muscle fibers, therefore allowing a residual Cox15 activity to
be maintained; and all of the reported SCO2 and COX15mutant
patients carried missense changes that do not disrupt the
corresponding proteins and, presumably, determine a decrease
but not the complete loss of their activity. Therefore, all mouse
models used in this work carry ‘‘permissive’’ defects that are
Figure 6. AICAR Treatment in ACTA-Cox15–/– Mice
(A) Expression analysis of FAO- and OXPHOS-related genes in ACTA-Cox15/ and WT muscles of AICAR-treated (0.5 mg/day/gm) and untreated mice. Solid
blue, WT, untreated; blue outline, AICAR-treated WT; solid red, ACTA-Cox15/, untreated; red outline, AICAR-treated ACTA-Cox15/. The levels of the gene
transcripts, retrotranscribed into cDNA, were normalized to that of the Hprt gene transcript and expressed as time-fold variation relative to the WT. Error bars
represent SD. The asterisks represent the significance levels calculated by unpaired, Student’s two-tailed t test: *p < 0.05; **p < 0.01; ***p < 0.001.
(B) Western blot immunovisualization of skeletal muscle proteins of the different genotypes, listed as above. Densitometric analysis of each band, normalized
against that of GAPDH, revealed the following variations, relative to untreated WT. (1) PGC-1a: 0.9 in WT+AICAR; 1.0 in ACTA-Cox15/; 1.8 in
ACTA-Cox15/+AICAR. (2) Total AMPK: 1.8 in WT+AICAR; 1.2 in ACTA-Cox15/; 1.0 in ACTA-Cox15/+AICAR. (3) AMPK-PT172: 4 in WT+AICAR; 11.0
in ACTA-Cox15/; 18.0 in ACTA-Cox15/+AICAR. COX1: 1.1 in WT+AICAR; 0.06 in ACTA-Cox15/; 0.4 in ACTA-Cox15/+AICAR. (4) COX5a: 1.0 in
WT+AICAR; 0.1 in ACTA-Cox15/; 0.6 in ACTA-Cox15/+AICAR.
(C) MRC-specific activities in the different genotypes, AICAR-treated or untreated, expressed as nmoles/min/mg of protein. Note that the activity of cII has been
multiplied by 10 for visualization clarity. Error bars represent SD.
(D) COX (upper panel) and SDH (middle panel) staining in AICAR-treated and untreated ACTA-Cox15/ andWTmuscle. Magnification, 203. Note the increased
staining of the ACTA-Cox15/+AICAR sections. (Bottom) EM of muscles from untreated and AICAR-treated muscles. Note the reduction of abnormal mito-
chondria in the AICAR-treated mouse.
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biogenesis.
We first stimulated the PPAR axis using bezafibrate, a pan-
PPAR agonist, in two COX-defective models: Surf1/, associ-
ated with mild COX deficiency and no clinical phenotype, and
ACTA-Cox15/, associated with profound COX deficiency
and severe mitochondrial myopathy. In spite of the fact that
FAO-related genes were in fact induced in treated animals,
thus demonstrating that bezafibrate was pharmacologically
active, we found neither stimulation of mitochondriogenesis
nor induction of MRC enzyme activities, in both Surf1/ and
WT animals, which developed instead marked hepatomegaly
and body weight loss. The toxic effects of bezafibrate were
even more dramatic and rapid in the ACTA-Cox15/ mouse
model. Albeit still unknown, the mechanism of the bezafibrate-
associated toxicity must be related to the muscle-specific
ablation of Cox15, and is possibly linked to the very severe
COX deficiency present in the skeletal muscle of these animals,since we showed that bezafibrate did not interfere with the
maintenance of the gene in extramuscular tissues of the
ACTA-Cox15/ model (data not shown). Albeit less dramatic
than the toxic myopathy observed in theACTA-Cox15/model,
adverse effects, such as body weight loss and hepatomegaly,
were also observed in other bezafibrate-treated animal models,
including mice with milder COX deficiency, such as (1) our con-
stitutive Surf1/mouse model (Figure S1); and (2) the Sco2KO/KI
mouse (E.A.S., unpublished data); as well as in animals with
other OXPHOS defects, such as (3) constitutive Mpv17/
mice (C.V. and M.Z., unpublished data). On a practical side,
we believe that these observations in mice should prompt
physicians to be cautious on the use of bezafibrate in patients
with severe MRC defects, particularly COX deficiencies.
We then activated the PGC-1a axis by treating our mouse
models with the AMPK agonist AICAR. Interestingly, we found
that the levels of activated AMPK-P172 were already higher in
skeletal muscle of untreated COX-defective models than in WTCell Metabolism 14, 80–90, July 6, 2011 ª2011 Elsevier Inc. 87
Figure 7. Treadmill Test
(A) Box-and-whisker plot of treadmill tests administered toWT (n. 16), Surf1/
(n. 11), Sco2KO/KI (n. 9), and ACTA-Cox15/ (n. 11) mice at 3 months of age.
There is no motor impairment in Surf1/; significant motor impairment in
Sco2KO/KI and severe motor impairment in ACTA-Cox15/mice compared to
WT mice. The vertical bars represent the range of values; the boxes represent
the values from the lower to upper quartile; the horizontal lines represent the
median value for each group of animals. ***, unpaired, Student’s two-tailed
t test: p < 106.
(B) Treadmill test in AICAR-treated Sco2KO/KI and in untreated Sco2KO/KI and
WT littermates. Each group was composed of four individuals. The scores of
motor performance measured week by week showed significant improvement
in the AICAR-treated Sco2KO/KI animals during the first 3 weeks of treatment
(paired, Student’s two-tailed t test ***p < 0.001; **p < 0.01; *p < 0.05), with an
additional, albeit not significant, increment at week 4. Notably, the score of the
AICAR-treated Sco2KO/KI animals became not significantly different from that
of untreated WT littermates at the end of the first week, identical to that of WT
at the second week, and significantly higher at the third and fourth weeks of
treatment. Note that untreated WT or Sco2KO/KI mice showed no change in
motor performance over time, indicating no significant effect of training.
Vertical bars show the SDs.
(C) Treadmill test in untreated and AICAR-treated ACTA-Cox15/ mice. No
change was detected in motor performance over time. Vertical bars show
the SDs.
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finding could be occurring because of the homeostatic loop
that relates the PGC-1a axis to the activity of MRC (Wallace88 Cell Metabolism 14, 80–90, July 6, 2011 ª2011 Elsevier Inc.and Fan, 2010), and can explain why the response of the latter
to AICAR was significantly higher in COX-defective muscles
than in WT muscles.
The 1.5-fold increase of PGC1a transcript and AMPK-
dependent activation of the corresponding protein induced by
AICAR did not determine an increase of the mtDNA content of
skeletal muscle, as observed in theMCK-PGC1amodels, where
PGC1a is >10-fold expressed compared to WT muscle. This
result suggests that the increase of OXPHOS-related proteins
and activities, including COX, that was observed in AICAR-
treated COX-defective mice, are likely due to increased
transcription and translation of the corresponding genes, in
agreement with the increased levels of Tfam expression. Impor-
tantly, the Sco2KO/KI mice, which are characterized by mild, but
significant, motor impairment, didmarkedly improve their perfor-
mance under AICAR treatment, in parallel with recovery of COX
activity in skeletal muscle. Unfortunately, no motor impairment
was measured in untreated Surf1/ mice (Figure 7A), which
prevented us from further investigating the clinical features of
this model under AICAR treatment. Contrariwise, the ACTA-
COX15/ mouse model showed very severe impairment of
motor performance at 2 months of age, which failed to respond
to AICAR, in spite of doubling the daily dosage of the drug
(0.5mg/gm versus 0.25mg/gm). Further dosage increase, earlier
and prolonged treatment, and association with other drugs (e.g.,
antioxidants) are warranted in this model to possibly improve
clinical efficacy. Unlike the results obtained with AICAR, bezafi-
brate had no effect on OXPHOS, whereas it was clearly effective
in inducing FAO-related genes. Acute exposure of MRC-defec-
tive cultured fibroblasts to high-dose bezafibrate has given
controversial results (Bastin et al., 2008): some cell lines did
respond by increasing MRC activities, others, including a
Surf1/ cell line, did not, which suggests that the responsive-
ness to the drug may depend on a number of still undisclosed
variables, possibly intrinsic to the cell type and culturing condi-
tions. Likewise, we have no obvious explanation for the discrep-
ancy between our results and those recently reported in the
MLC1F-Cox10/ mouse model. One possibility is that the
MLC1F-Cox10/ model is characterized by predominant exci-
sion of the Cox10 gene in fast-twitch, type 2, glycolytic muscle
fibers, whereas the slow-twitch, type 1, oxidative fibers are rela-
tively spared. Therefore, a shift in favor of the latter type induced
by bezafibrate-dependent activation of PPARs could explain the
improvement in COX activity, exercise performance, and eventu-
ally life span of the treated animals. Nevertheless, other effects
reported with this model, for instance increased expression of
Pgc1a, were not observed in ours. One reason may be related
to the fact that the PPAR system acts on Pgc1a via FAO induc-
tion and stimulation of NAD+-dependent Sirt1 deacetylase
(Gerhart-Hines et al., 2007); however, block of mitochondrial
respiration, as occurs in COX deficiency, typically decreases
the NAD+/NADH ratio and should in fact reduce the activation
of Sirt1 (Wallace, 2005), thus opposing the effect of PPAR
activation.
Taken together, the results of our study prove that pharmaco-
logical activation ofmitochondrial biogenesis is a rational, poten-
tially effective approach to mitochondrial disease. Nevertheless,
since both AICAR and activated AMPKdetermine a host of pleio-
tropic effects on different regulatory and homeostatic pathways
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animals is needed to establish treatment safety and eventual
translatability to humans.
EXPERIMENTAL PROCEDURES
Reagents and Materials
AICAR was from Toronto Research Chemicals. Anti-PGC-1a antibody was
from Abcam; anti-AMPK and anti-AMPK-P antibodies were from Cell
Signaling; anti-COI and -COX5a were from Invitrogen; anti-GAPDH was from
Millipore. Anti-rabbit and anti-mouse secondary antibodies were from Amer-
sham. Chemicals were from Sigma. MCK-PGC-1a and ACTA-Cre transgenic
mice were obtained from Jackson Laboratory, Bar Harbor, USA. Oligonucleo-
tides were from PRIMM, Italy. The sequences of all the primers used in this
study are available on request.
Western Blot Analysis
Total homogenates were prepared in RIPA buffer (50 mM Tris HCl [pH 8],
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) with the
addition of a protease inhibitor cocktail (Roche). Protein concentration was
determined by the Lowry method. Aliquots, 80 mg each, were run through
a 12% SDS-PAGE and electroblotted onto a nitrocellulose membrane, which
was then matched with different antibodies.
In Vivo Experiments
Animal studies were in accordance with the Italian Law D.L. 116/1992 and the
EUdirective 86/609/CEE. Standard food andwater were given ad libitum.Mice
were maintained in a temperature- and humidity-controlled animal-care
facility, with a 12 hr light/dark cycle and free access to water and food (Stan-
dard Diet, Mucedola, Italy). Bezafibrate (Sigma) 0.5%was added to a standard
diet (Mucedola, Italy) and administered for 1 month. AICAR or vehicle was
administered for 4 weeks with a single daily subcutaneous injection. No differ-
ence in daily monitored water and food intake was detected between the
treated versus untreated groups of animals during the experiment. Animals
were sacrificed by cervical dislocation.
Treadmill Test
A treadmill apparatus (Columbus Instruments, Columbus, OH) was used to
measure motor exercise endurance according to the number of falls in the
motivational grid during a gradually accelerating program with speed initially
at 6.5 m/min and increasing by 0.5m/min every 3min. The test was terminated
by exhaustion, defined as >10 falls/min into the motivational grid.
Morphological Analysis
Histochemical and ultrastructural analyses were performed as described
(Sciacco and Bonilla, 1996; Dubowitz, 1985). TUNEL reaction was performed
following the manufacturer’s instructions (In Situ Cell Death Detection Kit,
Roche, Germany).
Biochemical Analysis of MRC Complexes
Muscle quadriceps samples stored in liquid nitrogen were homogenized in
10 mM phosphate buffer (pH 7.4), and the spectrophotometric activity of cI,
cII, cIII and cIV, as well as CS, was measured as described (Bugiani et al.,
2004).
Real-Time PCR
For mtDNA content analysis, SYBRGreen real-time PCRwas performed using
primers specific to a mouse mtDNA region in the COI gene and primers
specific to RNaseP, a single copy gene taken as a nuclear gene reference,
as described (Viscomi et al., 2009). For the analysis of transcripts, total RNA
was extracted from liquidnitrogen snap frozen muscle by Trizol, according
to the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). Of total
RNA, 2 mg was treated with RNase free-DNase and retrotranscribed using
the ‘‘cDNA cycle’’ kit (Invitrogen, Carlsbad, CA, USA). Approximately 2–5 ng
of cDNA was used for real-time PCR assay using primers specific for amplifi-
cation of several genes.Creation of a Recombinant Cox15 KO Mouse
A mouse genomic region spanning Cox15 exons 1–2 was PCR amplified with
suitable oligos to introduce a loxP site, and cloned into a vector containing
a Neomycin resistance cassette, flanked by two Flp sites, and a second
loxP site. The short and long arms of homology were amplified by PCR using
suitable oligos and cloned into the vector containing the floxed region. The final
targeting vector was linearized by digestion with XhoI and electroporated in
129Sv cells. A total of 600 clones were PCR screened by PCR (see legend
of Figure S2). In one recombinant clone, homologous recombination was as-
certained on the long arm by long-range PCR (see Figure S2). Injection into
C57Bl/6 blastocysts was followed by selection of chimaeric individuals, which
were then backcrossed to a C57Bl/6 female. The recombinant mice were
crossed to a general deleter cre transgenic mouse to obtain Cox15+/ hetero-
zygous mice, which were then crossed to a Flpe transgenic mouse in order to
eliminate the neomycin-resistance cassette, resulting in Cox15lox/lox individ-
uals. ACTA-Cox15/ mice were eventually obtained by crossing Cox15lox/lox
with ACTA-Cre mice.SUPPLEMENTAL INFORMATION
Supplemental Information includes four tables and three figures and can be
found with this article online at doi:10.1016/j.cmet.2011.04.011.ACKNOWLEDGMENTS
This work was supported by the Pierfranco and Luisa Mariani Foundation Italy;
Fondazione Telethon-Italy grants numbers GGP07019 andGPP10005; Fonda-
zione Tomasello and Associazione Mitocon to M.Z.; the National Institutes of
Health (grant HD32062), the Muscular Dystrophy Association, and the Marriott
Mitochondrial Disorder Clinical Research Fund to E.A.S.; and the ‘‘Associa-
zione Amici del Centro Dino Ferrari’’ to M.M.
Received: January 19, 2011
Revised: March 23, 2011
Accepted: April 8, 2011
Published: July 5, 2011REFERENCES
Antonicka, H., Mattman, A., Carlson, C.G., Glerum, D.M., Hoffbuhr, K.C.,
Leary, S.C., Kennaway, N.G., and Shoubridge, E.A. (2003). Mutations in
COX15 produce a defect in the mitochondrial heme biosynthetic pathway,
causing early-onset fatal hypertrophic cardiomyopathy. Am. J. Hum. Genet.
72, 101–114.
Barish, G.D., Narkar, V.A., and Evans, R.M. (2006). PPAR delta: a dagger in the
heart of the metabolic syndrome. J. Clin. Invest. 116, 590–597.
Bastin, J., Aubey, F., Rotig, A., Munnich, A., and Djouadi, F. (2008). Activation
of peroxisome proliferator activated receptor pathway stimulates the mito-
chondrial respiratory chain and can correct deficiencies in patients’ cells lack-
ing its components. J. Clin. Endocrinol. Metab. 4, 1433–1441.
Bugiani, M., Invernizzi, F., Alberio, S., Briem, E., Lamantea, E., Carrara, F.,
Moroni, I., Farina, L., Spada, M., Donati, M.A., et al. (2004). Clinical and molec-
ular findings in children with complex I deficiency. Biochim. Biophys. Acta
1659, 136–147.
Bugiani, M., Tiranti, V., Farina, L., Uziel, G., and Zeviani, M. (2005). Novel
mutations in COX15 in a long surviving Leigh syndrome patient with cyto-
chrome c oxidase deficiency. J. Med. Genet. 42, e28. 10.1136/jmg.2004.
029926.
Canto´, C., and Auwerx, J. (2010). AMP-activated protein kinase and its down-
stream transcriptional pathways. Cell. Mol. Life Sci. 67, 3407–3423.
Canto´, C., Gerhart-Hines, Z., Feige, J.N., Lagouge, M., Noriega, L., Milne, J.C.,
Elliott, P.J., Puigserver, P., and Auwerx, J. (2009). AMPK regulates energy
expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature
458, 1056–1060.Cell Metabolism 14, 80–90, July 6, 2011 ª2011 Elsevier Inc. 89
Cell Metabolism
COX Defect Correction by AMPK/PGC-1a ActivationCharach, G., Grosskopf, I., Rotmensch, H.H., Kitzis, I., and Weintraub, M.
(2005). Bezafibrates cause moderate, reversible impairment in renal function
in patients without prior renal disease. Nephron Clin. Pract. 100, c120–c125.
Corton, J.M., Gillespie, J.G., Hawley, S.A., and Hardie, D.G. (1995). 5-amino-
imidazole-4-carboxamide ribonucleoside. A specific method for activating
AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558–565.
Cree, L.M., Patel, S.K., Pyle, A., Lynn, S., Turnbull, D.M., Chinnery, P.F., and
Walker, M. (2008). Age-related decline in mitochondrial DNA copy number in
isolated human pancreatic islets. Diabetologia 51, 1440–1443.
Dell’Agnello, C., Leo, S., Agostino, A., Szabadkai, G., Tiveron, C., Zulian, A.,
Prelle, A., Roubertoux, P., Rizzuto, R., and Zeviani, M. (2007). Increased
longevity and refractoriness to Ca(2+)-dependent neurodegeneration in
Surf1 knockout mice. Hum. Mol. Genet. 16, 431–444.
Dubowitz, V. (1985). Muscle Biopsy, A Practical Approach, 2nd ed. (London:
Baillie`re Tindall).
Fogarty, S., Hawley, S.A., Green, K.A., Saner, N., Mustard, K.J., and Hardie,
D.G. (2010). Calmodulin-dependent protein kinase kinase-b activates AMPK
without forming a stable complex: synergistic effects of Ca2+ and AMP.
Biochem. J. 426, 109–118.
Gerhart-Hines, Z., Rodgers, J.T., Bare, O., Lerin, C., Kim, S.H., Mostoslavsky,
R., Alt, F.W., Wu, Z., and Puigserver, P. (2007). Metabolic control of muscle
mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha.
EMBO J. 26, 1913–1923.
Goldman, S.J., Taylor, R., Zhang, Y., and Jin, S. (2010). Autophagy and the
degradation of mitochondria. Mitochondrion 10, 309–315.
Handschin, C., and Spiegelman, B.M. (2006). Peroxisome proliferator-
activated receptor gamma coactivator 1 coactivators, energy homeostasis,
and metabolism. Endocr. Rev. 27, 728–735.
Ja¨ger, S., Handschin, C., St-Pierre, J., and Spiegelman, B.M. (2007). AMP-
activated protein kinase (AMPK) action in skeletal muscle via direct phosphor-
ylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA 104, 12017–12022.
Kelly, D.P., and Scarpulla, R.C. (2004). Transcriptional regulatory circuits
controlling mitochondrial biogenesis and function. Genes Dev. 18, 357–368.
Khalimonchuk, O., and Ro¨del, G. (2005). Biogenesis of cytochrome c oxidase.
Mitochondrion 5, 363–388.
Kleiner, S., Nguyen-Tran, V., Bare´, O., Huang, X., Spiegelman, B., and Wu, Z.
(2009). PPAR{delta} agonism activates fatty acid oxidation via PGC-1{alpha}
but does not increase mitochondrial gene expression and function. J. Biol.
Chem. 284, 18624–18633.
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin,
F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006). Resveratrol
improves mitochondrial function and protects against metabolic disease by
activating SIRT1 and PGC-1alpha. Cell 127, 1109–1122.
Leary, S.C., Sasarman, F., Nishimura, T., and Shoubridge, E.A. (2009). Human
SCO2 is required for the synthesis of CO II and as a thiol-disulphide oxidore-
ductase for SCO1. Hum. Mol. Genet. 18, 2230–2240.
Lefebvre, P., Chinetti, G., Fruchart, J.C., and Staels, B. (2006). Sorting out the
roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin.
Invest. 116, 571–580.
Lin, J., Wu, H., Tarr, P.T., Zhang, C.-Y., Wu, Z., Boss, O., Michael, L.F.,
Puigserver, P., Isotani, E., Olson, E.N., et al. (2002). Transcriptional co-acti-
vator PGC-1a drives the formation of slow-twitch muscle fibers. Nature 418,
797–801.90 Cell Metabolism 14, 80–90, July 6, 2011 ª2011 Elsevier Inc.Luquet, S., Lopez-Soriano, J., Holst, D., Fredenrich, A., Melki, J.,
Rassoulzadegan, M., and Grimaldi, P.A. (2003). Peroxisome proliferator-acti-
vated receptor delta controls muscle development and oxidative capability.
FASEB J. 17, 2299–2301.
Merrill, G.F., Kurth, E.J., Hardie, D.G., and Winder, W.W. (1997). AICA riboside
increases AMP-activated protein kinase, fatty acid oxidation, and glucose
uptake in rat muscle. Am. J. Physiol. 273, 1107–1112.
Papadopoulou, L.C., Sue, C.M., Davidson, M.M., Tanji, K., Nishino, I.,
Sadlock, J.E., Krishna, S., Walker, W., Selby, J., Glerum, D.M., et al. (1999).
Fatal infantile cardioencephalomyopathy with COX deficiency and mutations
in SCO2, a COX assembly gene. Nat. Genet. 23, 333–337.
Sciacco, M., and Bonilla, E. (1996). Cytochemistry and immunocytochemistry
of mitochondria in tissue sections. Methods Enzymol. 264, 509–521.
Srivastava, S., Diaz, F., Iommarini, L., Aure, K., Lombes, A., and Moraes, C.T.
(2009). PGC-1alpha/beta induced expression partially compensates for
respiratory chain defects in cells from patients with mitochondrial disorders.
Hum. Mol. Genet. 18, 1805–1812.
Steinberg, G.R., and Kemp, B.E. (2009). AMPK in health and disease. Physiol.
Rev. 89, 1025–1078.
Tenenbaum, A., Motro, M., and Fisman, E.Z. (2005). Dual and pan-peroxisome
proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Cardiovasc. Diabetol. 16, 4–14.
Tiranti, V., Galimberti, C., Nijtmans, L., Bovolenta, S., Perini, M.P., and Zeviani,
M. (1999). Characterization of SURF-1 expression and Surf-1p function in
normal and disease conditions. Hum. Mol. Genet. 8, 2533–2540.
Viscomi, C., Spinazzola, A., Maggioni, M., Fernandez-Vizarra, E., Massa, V.,
Pagano, C., Vettor, R., Mora, M., and Zeviani, M. (2009). Early-onset liver
mtDNA depletion and late-onset proteinuric nephropathy in Mpv17 knockout
mice. Hum. Mol. Genet. 18, 12–26.
Wallace, D.C. (2005). Amitochondrial paradigm ofmetabolic and degenerative
diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev.
Genet. 39, 359–407.
Wallace, D.C. (2010). Mitochondrial energetics and therapeutics. Annu. Rev.
Pathol. 5, 297–348.
Wallace, D.C., and Fan, W. (2010). Energetics, epigenetics, mitochondrial
genetics. Mitochondrion 10, 12–31.
Wang, Y.X., Zhang, C.L., Yu, R.T., Cho, H.K., Nelson, M.C., Bayuga-Ocampo,
C.R., Ham, J., Kang, H., and Evans, R.M. (2004). Regulation of muscle fiber
type and running endurance by PPARdelta. PLoS Biol. 2, e294. 10.1371/jour-
nal.pbio.0020294.
Wenz, T., Diaz, F., Spiegelman, B.M., and Moraes, C.T. (2008). Activation of
the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively
improves a mitochondrial myopathy phenotype. Cell Metab. 8, 249–256.
Wu, J., Song, Y., Li, H., and Chen, J. (2009). Rhabdomyolysis associated with
fibrate therapy: review of 76 published cases and a new case report. Eur. J.
Clin. Pharmacol. 65, 1169–1174.
Yang, H., Brosel, S., Acin-Perez, R., Slavkovich, V., Nishino, I., Khan, R.,
Goldberg, I.J., Graziano, J., Manfredi, G., and Schon, E.A. (2010). Analysis
of mouse models of cytochrome c oxidase deficiency owing to mutations in
Sco2. Hum. Mol. Genet. 19, 170–180.
Zeviani, M., and Di Donato, S. (2004). Mitochondrial disorders. Brain 127,
2153–2172.
